Austrian expert panel recommendation for radiofrequency ablation of Barrett’s esophagus
- 334 Downloads
Barrett’s esophagus (BE) represents the premalignant manifestation of gastroesophageal reflux disease and includes columnar lined esophagus with intestinal metaplasia, low-grade dysplasia, high-grade dysplasia and cancer.
An Austrian panel of expert meeting was held at the Medical University Vienna, June 2015, to establish and define recommendations for the endoscopic treatment of BE with and without dysplasia and cancer. Recommendations are based on critical analysis of published evidence. Statistics were not applied.
Diagnosis of cancer and dysplasia is to be reconfirmed by a second expert pathologist. Advanced cancer (> T1a) requires surgical resection ± adjuvant therapies. Treatment of T1a early cancer, high- and low-grade dysplasia should include endoscopic mucosal resection (EMR) and radiofrequency ablation (RFA). In the presence of increased cancer risk, BE without dysplasia should be treated by RFA within clinical studies only. Elimination of any early cancer, dysplasia and IM defines complete response, that is, post RFA histopathology shows squamous, cardiac or oxyntocardiac mucosa lined esophagus (Chandrasoma classification). Follow-up endoscopies are timed according to the base line histopathology. Down grade from cancer to dysplasia or from dysplasia to non-dysplastic BE defines partial response, respectively. Based on esophageal function testing, reflux is treated by medical or surgical therapy.
In Austria, RFA ± EMR is recommended for BE containing early cancer or dysplasia. Non-dysplastic BE with an increased cancer risk should be offered RFA within clinical trials to assess the efficacy for cancer prevention in this group of patients.
KeywordsBarrett’s esophagus Dysplasia Esophageal cancer Radiofrequency ablation
The authors thank their patients for giving them the opportunity to learn about Barrett’s esophagus diagnosis and treatment. In addition, the authors express their gratitude to their supportive teachers, families and friends. May the open-minded approach continue to foster the development of future diagnosis and therapy of Barrett’s esophagus.
Conflict of interest
The authors declare that there are no actual or potential conflicts of interest in relation to this article.
- 6.Rees JR, Lao-Sirieix P, Wong A, Fitzgerald RC, Treatment for Barrett’s oesophagus. Cochrane Database Syst Rev. 2010(1):CD004060.Google Scholar
- 8.Statistik A. Austrian cancer and causes of death register. Version 17.10.2013, published online. Accessed July 2015.Google Scholar
- 14.van Vilsteren FG, Alvarez Herrero L, Pouw RE, Schrijnders D, Sondermeijer CM, Bisschops R, et al. Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett’s esophagus with early neoplasia: a prospective multicenter study. Endoscopy. 2013;45(7):516–25.CrossRefPubMedGoogle Scholar
- 16.Phoa KN, Pouw RE, Bisschops R, Pech O, Ragunath K, Weusten BL, et al. Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II). Gut. 2015 doi: 10.1136/gutjnl-2015-309298.
- 25.Attwood SE, Ell C, Galmiche JP, Fiocca R, Hatlebakk JG, Hasselgren B, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015;41(11):1162–74.CrossRefPubMedGoogle Scholar